Abstract
KRN5500 is a highly active new semi‐synthetic water‐insoluble anticancer agent. The only mechanism of anticancer activity of KRN5500 described so far is an inhibitory effect on protein synthesis. At the tune of writing, a phase I clinical trial is under way at the National Cancer Center Hospital, Tokyo, and at the National Cancer Institute in the USA. Although preclinical data did not indicate lung toxicity, some cases of severe pulmonary disorder were reported in the phase I clinical trials. This study has been conducted to examine whether incorporation of KRN5500 into polymeric micelles (KRN/m) could reduce the toxic effects caused by the current formulation of KRN5500. The in vitro and in vivo antitumor activities of KRN5500 and KRN/m were compared. Pulmonary toxicity of KRN5500 and KRN/m was studied using a bleomycin (BLM)‐induced lung injury rat model. In BLM‐rats, extensive pulmonary hemorrhage with diapedesis was observed with KRN5500 i.v. bolus injection at the dose of 3 mg/kg, which is equivalent to 21.0 mg/m2 (level 5) of the Japanese phase I trial. However, toxicity was not observed when rats were administered KRN/m at the equivalent dose to KRN5500 in potency. Electron microscopy of the lung treated with KRN5500 showed disruption of the alveolar type II membrane with release of lamellar debris. Furthermore, in vivo, KRN/m showed similar antitumor activity to KRN5500. These results indicate that KRN/m may be useful for reducing the pulmonary toxicity associated with the current formulation of KRN5500, while fully maintaining its antitumor activity.
Keywords: Drug delivery system, Polymer micelles, KRN5500, Pulmonary toxicity, Tumor targeting
Full Text
The Full Text of this article is available as a PDF (2.1 MB).
REFERENCES
- 1. ) Kamishouhara , M. , Kawai , H. , Odagawa , A. , Isoe , T. , Mochizuki , J. , Uchida , T. , Hayakawa , Y. , Seto , H. , Tsuruo , T. and Otake , N.Antitumor activity of SPM VIII, derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts . J. Antibiot. (Tokyo) , 47 , 1305 – 1311 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Kamishouhara , M. , Kawai , H. , Sakai , T. , Isoe , H. , Hasegawa , K. , Mochizuki , J. , Uchida , T. , Kataoka , S. , Yamaki , H. , Tsuruo , T. and Otake , N.Antitumor activity of a spicamycin derivative, KRN5500, and its activity metabolite in tumor cells . Oncol. Res. , 6 , 383 – 390 ( 1994. ). [PubMed] [Google Scholar]
- 3. ) Sakai , T. , Kawai , H. , Kamishouhara , M. , Odagawa , A. , Suzuki , A. , Uchida , T. , Kawasaki , T. , Tsuruo , T. and Otake , N.Structure‐antitumor activity relationship of semi‐synthetic spicamycin derivatives . J. Antibiot. (Tokyo) , 48 , 1467 – 1480 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Matsumura , Y. , Kamiya , Y. , Yamamoto , N. , Ono , H. , Shirao , K. , Kondo , H. , Tamura , T. and Shimada , Y.A phase I study of KRN5500 in patients with refractory solid tumors (stomach, colon, lung) . Proc. Am. Soc. Clin. Oncol. , 18 , 219 (abstr. 841) ( 1999. ). [Google Scholar]
- 5. ) Eder , J. P. , Supko , J. G. , Ryan , K. , Roper , N. , Kinchla , D. P. and Kufe , D. W. A.Phase I trial of the spicamycin analogue KRN5500 . Proc. Am. Assoc. Cancer Res. , 40 , 91 (abstr. 604) ( 1999. ). [Google Scholar]
- 6. ) Yokoyama , M. , Satoh , A. , Sakurai , Y. , Okano , T. , Matsumura , Y. , Kakizoe , T. and Kataoka , K.Incorporation of water‐insoluble anticancer drug into polymeric micelles and control of their particle size . J. Controlled Release , 55 , 219 – 229 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 7. ) Matsumura , Y. , Yokoyama , M. , Kataoka , K. , Okano , T. , Sakurai , Y. , Kawaguchi , T. and Kakizoe , T.Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles . Jpn. J. Cancer Res. , 90 , 122 – 128 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. ) Thrall , R. S. , McCormick , J. R. , Jack , R. M. , McReynolds , R. A. and Ward , P. A.Bleomycin‐induced pulmonary fibrosis in the rat: inhibition by indomethacin . Am. J. Pathol. , 95 , 117 – 130 ( 1979. ). [PMC free article] [PubMed] [Google Scholar]
- 9. ) Adamsom , I. Y. R. and Bowden , D. H.The pathogenesis of bleomycin‐inducing pulmonary fibrosis in mice . Am. J. Pathol , 77 , 185 – 198 ( 1974. ). [PMC free article] [PubMed] [Google Scholar]
- 10. ) Bader , H. , Ringsdorf , H. and Schmidt , B.Water‐soluble polymers in medicine . Angew. Makromol. Chem. , 123/124 , 457 – 485 ( 1984. ). [Google Scholar]
- 11. ) Yokoyama , M. , Miyauchi , M. , Yamada , N. , Okano , T. , Sakurai , Y. , Kataoka , K. and Inoue , S.Characterization and anticancer activity of micelle‐forming polymeric antitumor drug adriamicin‐conjugated poly(ethylene glycol)‐poly(aspartic acid) block copolymer . Cancer Res. , 50 , 1693 – 1700 ( 1990. ). [PubMed] [Google Scholar]
- 12. ) Yokoyama , M. , Okano , T. , Sakurai , Y. , Ekimoto , H. , Shibazaki , C. and Kataoka , K.Toxicity and antitumor activity against solid tumors of micelle‐forming polymeric antitumor drug and its extremely long circulation in blood . Cancer Res. , 51 , 3229 – 3236 ( 1991. ). [PubMed] [Google Scholar]
- 13. ) Yokoyama , M. , Okano , T. , Sakurai , Y. , Suwa , S. and Kataoka , K.Introduction of cisplatin into micelle . J. Controlled Release , 39 , 351 – 356 ( 1996. ). [Google Scholar]
- 14. ) Nishiyama , N. , Yokoyama , M. , Aoyagi , T. , Okano , T. , Sakurai , Y. and Kataoka , K.Preparation and characterization of self‐assembled polymer‐metal complex micelle from cis‐dichlorodiammineplatinum (II) and poly(ethylene glycol)‐poly(α,β‐aspartic acid) block copolymer in an aqueous medium . Langmuir , 15 , 377 – 383 ( 1999. ). [Google Scholar]
- 15. ) Burger , A. M. , Kaur , G. , Hollingshead , M. , Fischer , R. T. , Nagashima , K. , Malspeis , L. , Duncan , K. L. K. and Sausville , E. A.Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered gly‐coprotein expression in vitro . Clin. Cancer Res. , 3 , 455 – 463 ( 1997. ). [PubMed] [Google Scholar]
- 16. ) Lee , Y. S. , Nishio , K. , Ogasawana , H. , Funayama , Y. , Ohira , T. and Saijo , N.In vitro cytotoxicity of a novel anti‐tumor antibiotic, spicamycin derivative, in human lung cancer cell lines . Cancer Res. , 55 , 1075 – 1079 ( 1995. ). [PubMed] [Google Scholar]
- 17. ) Takara , K. , Tanigawara , Y. , Komada , F. , Nishiguchi , K. , Sakaeda , T. and Okamura , K.The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P‐glycoprotein . Jpn. J. Cancer Res. , 91 , 248 – 254 ( 2000. ). [DOI] [PMC free article] [PubMed] [Google Scholar]